Hamilton, Ontario June 23, 2020 The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18, 2020. Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie, outgoing Chair of
Radiopharmaceuticals are a special class of drugs. They’re sometimes called molecular imaging probes, contrast agents, tracers or radiotherapeutics.
Radiopharmaceuticals contain a radioactive isotope and they are used to both diagnose and treat disease. Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.
VANCOUVER, Canada and NEW YORK, United States, May 20, 2020 – ARTMS Inc. a global leader in developing technology that transforms the production of the world’s most-used diagnostic imaging isotopes, today announced that it has raised US$19 million in a Series A financing. The investment was led by New York based Deerfield Management Company with
CPDC is always looking for exceptional people to strengthen our team.